Bullous pemphigoid
Conditions
Interventions
Telitacicept in the Treatment of Adult Patients with Bullous Pemphigoid:NA
Sponsors
Hospital for Skin Diseases, Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients meeting diagnostic criteria for bullous pemphigoid (a: clinical manifestations of flaccid vesicles, erosions on skin and mucous membranes, negative Nikolsky's sign; b: histopathological examination indicating subepidermal vesicles; c: direct immunofluorescence demonstrating IgG and/or C3 deposition in a reticular pattern at the basement membrane zone). 2. Adult patients aged 18-80 years. 3. Moderate-to-severe bullous pemphigoid (as measured by BPDAI score: mild =50 points); 4. First-time receipt of telitacicept treatment; 5. Provided written informed consent. 6. Able to adhere to the treatment schedule and follow-up protocol.
Exclusion criteria
Exclusion criteria: 1.Patients younger than 18 years or older than 80 years, those with contraindications including severe cardiovascular diseases, severe hepatic or renal impairment, severe active infections, history of severe infusion reactions, severe hypersensitivity to related drugs, history of malignancy, pregnant or breastfeeding women, individuals who recently received or plan to receive vaccinations, and patients previously treated with biologics such as telitacicept will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission off therapy;The proportion and time to achieve pathogenic antibodies converting to negative.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative glucocorticoid dose (prednisone equivalent);Relapse rates; | — |
Countries
China
Contacts
Public ContactHong Liu
Hospital for Skin Diseases, Shandong First Medical University
Outcome results
None listed